|View printer-friendly version|
Total Year 2002 EPS Guidance Raised to $1.41-$1.43 Strong Sales and EPS Growth Expected in 2003
Douglas E. Rogers Elected to Board of Directors
Charles River Laboratories International, Inc. (NYSE:CRL) today reported third-quarter 2002 income before extraordinary item of $18.9 million, a 60.2% increase over the $11.8 million reported in the third quarter of 2001. Earnings per share rose 50.0% to $0.39 per diluted share from $0.26 per diluted share reported last year. Net sales in the third quarter were $141.4 million compared to $123.7 million reported in 2001, an increase of 14.3%. Net income for the third quarter was $18.5 million, or $0.38 per diluted share, including an extraordinary charge of $0.4 million, or $0.01 per diluted share, for termination of a $30.0 million revolving credit facility. Interest expense for the third quarter was $1.9 million compared to $5.1 million in the third quarter of 2001.
Operating income in the third quarter of 2002 rose 35.4% to $32.5 million from $24.0 million in the same period in 2001. The Company's operating margin rose to 23.0%, a 360 basis point increase over the 19.4% margin achieved in the third quarter of last year, reflecting higher sales in both the research models and biomedical products and services businesses and operating efficiencies resulting from the increased volume.
Effective January 1, 2002, the Company adopted Statement of Financial Accounting Standards No. 142 (SFAS 142), "Goodwill and Other Intangible Assets." The effect of this change amounted to $0.02 per diluted share on the Company's third-quarter 2002 results and $0.06 per diluted share for the year to date.
James C. Foster, Chairman, President and Chief Executive Officer said, "For the ninth consecutive quarter since going public, Charles River has again delivered substantial growth in sales, margins, and earnings per share. Our solid and consistent financial performance reflects the leading share position we hold in a number of attractive markets and the strength of the growing drug discovery and development market.
Mr. Foster added, "We have built a strong and diverse portfolio of businesses that provide a comprehensive array of services in the non-clinical drug development field. We're extremely well positioned to be a key, strategic partner with our customers as they increasingly outsource the discovery and development of new drugs, diagnostics, and medical devices. We expanded the scale of our service offerings with the October 1, 2002, acquisition of Springborn Laboratories which strengthens both our geographic and client access position in the toxicology market. The October 2, 2002, addition of Charles River Proteomics Services, our 80/20 joint venture with Proteome Systems Ltd, positions us to become a market leader in the field of providing proteomics services."
Third-quarter 2002 net sales for the Research Models segment of the business were $56.8 million compared to $50.6 million last year. The 12.1% gain reflected increased customer demand for animal research models and higher sales of specialty models for pre-clinical drug development work. Significantly higher sales yielded a gross margin of 44.7% compared to 40.5% in the third quarter of last year. The sales increase also generated operating efficiencies which resulted in a 38.0% increase in operating income, to $18.6 million in the third quarter with an operating margin of 32.8%, compared to last year's $13.5 million and 26.6%.
Mr. Foster said, "Demand for research models continues to grow steadily. As pharmaceutical and biotech companies increase the number of compounds they are developing, there is a corresponding increase in their use of research models, particularly the specialty models used in research on diabetes, cardiovascular disease, and cancer as well as standard outbred strains used for drug safety testing. In order to keep pace with the demand, we have added to North American production capacity for the first time in over a decade."
Net sales for the Biomedical Products and Services segment rose 15.8% in the third quarter, to $84.6 million from $73.0 million in the same period last year. The Company's discovery services business, which includes transgenic, laboratory testing, and contract staffing services, had significant sales growth in the quarter, led by transgenic services. Sales for the development services business, which includes the entire range of pre-clinical drug testing services, also increased, with strong growth of drug safety assessment and biosafety testing for biotech companies producing drugs derived from human proteins. BioLabs, the Irish-based human and animal health sciences company acquired in June 2002, is performing well and in line with our expectations.
The third-quarter 2002 gross margin for the Biomedical Products and Services segment was 33.2%, a 210 basis point increase over the 31.1% achieved in last year's third quarter. Segment operating income rose 27.6% to $17.1 million from $13.4 million last year and the operating margin increased to 20.2% from 18.3%.
For the first nine months of 2002, income before extraordinary items rose 71.9% to $50.9 million from $29.6 million in the same period last year. Earnings per share were $1.06 per diluted share, a 55.9% increase over last year's $0.68 per diluted share. These results were driven by a 21.2% increase in net sales, to $411.7 million from $339.5 million last year.
Income before extraordinary items also improved due to a reduction in interest expense resulting from the issuance of $185.0 million of senior convertible debentures with an interest rate of 3.5% and the subsequent early retirement of the Company's 13.5% senior subordinated notes and its senior secured term loan facilities. Interest expense declined to $9.2 million in the nine-month period from $18.4 million in the same period last year.
Operating income for the nine-month period was $91.3 million, a 34.5% increase over the $67.9 million reported in the same period in 2001. The Company's operating margin rose to 22.2% compared to 20.0% in the third quarter of last year, reflecting higher sales and the resulting operating efficiencies and the effect of the adoption of SFAS 142.
The following forward-looking guidance is based on current exchange rates.
The Company now anticipates that net sales for the fourth quarter of 2002 will be approximately 15.0% higher than last year's fourth quarter due to continued growth in both the Research Models and Biomedical Products and Services segments. Diluted earnings per share are expected to be in a range of $0.35 to $0.37, reflecting higher sales and operating efficiencies. Fourth-quarter earnings per share are typically slightly lower than third-quarter, reflecting industry seasonality in the Research Models business segment. For the full year, the Company expects earnings per diluted share before extraordinary items of between $1.41 and $1.43, more than a 50.0% increase over 2001 results.
In 2003, the Company expects to see continuing growth in its business. Spending on pre-clinical research and development by the pharmaceutical and biotech industry is expected to increase and outsourcing of these services will continue. For these reasons, the Company expects net sales to advance by more than 15.0% and earnings per diluted share to grow at a faster rate than sales.
Rogers Elected to Board of Directors
At Charles River Laboratories' Board of Directors meeting on October 23, 2002, Douglas E. Rogers was elected a member of the Board. Mr. Rogers, who previously served on the Board from 1999 until 2001, has extensive experience in investment banking for the health care industry, most recently with Credit Suisse First Boston. Mr. Foster said, "We're very pleased to have Doug rejoin our Board. He worked with us throughout the LBO and public offering and has invaluable knowledge of the capital markets and of our industry. Doug further strengthens our already independent Board and we look forward to working with him again."
Charles River Laboratories has scheduled a live webcast on Wednesday, October 30, at 8:30 a.m. EST to discuss matters relating to this press release. To participate, please go to www.criver.com, Investor Relations, and select the webcast link. The webcast will be available until 5:00 p.m. EST on November 6, 2002.
Charles River Laboratories, based in Wilmington, Massachusetts, is a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development. The Company is the global leader in providing the animal research models required in research and development for new drugs, devices and therapies. The Company also offers a broad and growing portfolio of biomedical products and services that enable customers to reduce cost, increase speed, and enhance productivity and effectiveness in drug discovery and development. Charles River's customer base spans over 50 countries, and includes all of the major pharmaceutical and biotechnology companies, as well as many leading hospitals and academic institutions. The Company operates 76 facilities in 16 countries worldwide.
Caution Concerning Forward-Looking Statements. This document includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "estimate," "plan," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on management's current expectations, and involve a number of risks and uncertainties that could cause actual results to differ materially from those stated or implied by the forward-looking statements, and the company expressly does not undertake any duty to update forward-looking statements, which speak only as of the date of this document. Those risks and uncertainties include, but are not limited to: acquisition integration risks; special interest groups; contaminations; industry trends; new displacement technologies; outsourcing trends; USDA and FDA regulation; changes in law; continued availability of products and supplies; loss of key personnel; interest rate and foreign currency exchange rate fluctuations; and changes in generally accepted accounting principles. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in the Company's registration statement on Form S-3 as filed on April 9, 2002, with the Securities and Exchange Commission.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (dollars in thousands except for per share data) Three Months Ended Nine Months Ended Sept. 28, Sept. 29, Sept. 28, Sept. 29, 2002 2001 2002 2001 Total Net Sales $ 141,364 $ 123,685 $ 411,685 $ 339,536 Cost of products sold and services provided 87,889 80,474 255,851 215,893 Gross margin 53,475 43,211 155,834 123,643 Selling, general and administrative 20,023 17,016 62,329 49,761 Amortization of goodwill and intangibles 933 2,183 2,194 6,004 Operating income 32,519 24,012 91,311 67,878 Interest income (expense) (1,862) (5,096) (7,515) (17,395) Other income (expense) (48) 83 1,029 516 Income before taxes, minority interests, earnings from equity investments and extraordinary item 30,609 18,999 84,825 50,999 Provision for income taxes 11,041 6,677 32,185 19,891 Income before minority interests, earnings from equity investments and extraordinary item 19,568 12,322 52,640 31,108 Minority interests (717) (643) (2,098) (1,859) Earnings from equity investments 57 126 316 345 Net income before extraordinary item 18,908 11,805 50,858 29,594 Extraordinary loss, net of tax benefit (377) (1,284) (18,231) (3,104) Net income $ 18,531 $ 10,521 $ 32,627 $ 26,490 Earnings per common share before extraordinary item Basic $ 0.42 $ 0.27 $ 1.14 $ 0.74 Diluted $ 0.39 $ 0.26 $ 1.06 $ 0.68 Earnings per common share after extraordinary item Basic $ 0.41 $ 0.24 $ 0.73 $ 0.66 Diluted $ 0.38 $ 0.23 $ 0.70 $ 0.61 Weighted average number of common shares outstanding before and after extraordinary item Basic 44,916,369 43,054,478 44,583,773 39,953,655 Diluted 51,384,534 45,679,127 50,680,170 43,429,162 CHARLES RIVER LABORATORIES INTERNATIONAL, INC CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (dollars in thousands) September 28, December 29, 2002 2001 Assets Current assets Cash and cash equivalents $ 117,389 $ 58,271 Trade receivables 98,718 98,478 Inventories 41,921 39,056 Other current assets 15,892 14,349 Total current assets 273,920 210,154 Property, plant and equipment, net 174,548 155,919 Goodwill, net 78,650 52,087 Other intangibles, net 28,274 38,287 Deferred tax asset 77,128 87,781 Other assets 23,788 27,134 Total assets $ 656,308 $ 571,362 Liabilities and Shareholders' Equity Current liabilities Accounts payable $ 10,917 $ 13,868 Accrued compensation 28,185 25,736 Other current liabilities 61,797 58,928 Total current liabilities 100,899 98,532 Long-term debt 188,512 155,506 Other long-term liabilities 17,122 14,826 Total liabilities 306,533 268,864 Minority interests 16,935 12,988 Total shareholders' equity 332,840 289,510 Total liabilities and shareholders' equity $ 656,308 $ 571,362 CHARLES RIVER LABORATORIES INTERNATIONAL, INC SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED) (dollars in thousands) Three Months Ended Nine Months Ended Sept. 28, Sept. 29, Sept. 28, Sept. 29, 2002 2001 2002 2001 Research Models Net sales $56,771 $50,647 $170,214 $148,134 Gross margin 25,375 20,511 77,534 61,975 Gross margin as a % of sales 44.7% 40.5% 45.6% 41.8% Operating income 18,596 13,476 57,121 40,428 Operating income as a % of sales 32.8% 26.6% 33.6% 27.3% Depreciation amortization 2,472 2,474 7,013 7,210 Capital expenditures 2,954 2,309 9,493 6,701 Biomedical Products and Services Net sales $84,593 $73,038 $241,471 $191,402 Gross margin 28,100 22,700 78,300 61,668 Gross margin as a % of sales 33.2% 31.1% 32.4% 32.2% Operating income 17,093 13,394 47,531 34,350 Operating income as a % of sales 20.2% 18.3% 19.7% 17.9% Depreciation amortization 3,859 4,738 10,368 12,031 Capital expenditures 4,354 6,495 12,121 13,829 Unallocated Corporate Overhead ($3,170) ($2,858) ($13,341) ($6,900) Total Net sales $141,364 $123,685 $411,685 $339,536 Gross margin 53,475 43,211 155,834 123,643 Gross margin as a % of sales 37.8% 34.9% 37.9% 36.4% Operating income 32,519 24,012 91,311 67,878 Operating income as a % of sales 23.0% 19.4% 22.2% 20.0% Depreciation amortization 6,331 7,212 17,381 19,241 Capital expenditures 7,308 8,804 21,614 20,530CONTACT:
Charles River Laboratories International, Inc.
Susan E. Hardy, 978/658-6000, ext. 1616
Director, Investor Relations